ATOS Atossa Therapeutics
- 1.5650
- -0.0450-2.80%
Atossa Therapeutics News
Atossa Therapeutics Gives Final Dose in Breast Cancer Prevention Study | NASDAQ:ATOS
Atossa Therapeutics Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial
SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company") today announced that the last patient in the Company's Karisma-Endoxifen clinical trial
Atossa Therapeutics' Endoxifen Shows Promising Phase 2 Results, Secures Buy Rating
Cantor Fitzgerald Reiterates Overweight on Atossa Therapeutics
Cantor Fitzgerald analyst Louise Chen reiterates Atossa Therapeutics with a Overweight.
Atossa Therapeutics Files for $100M Mixed Shelf Offering
Atossa Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Atossa Therapeutics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Atossa Therapeutics, Raises Price Target to $6
HC Wainwright & Co. analyst Emily Bodnar maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $4 to $6.
Atossa Therapeutics Inc (ATOS) Q1 2024 Earnings: Aligns With Analyst Projections Amidst ...
Atossa Therapeutics (ATOS.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share of -$0.05, previous value of -$0.05, expected value of -$0.07.
Atossa Therapeutics (ATOS.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share of -$0.05, previous value of -$0.05, expected value of -$0.07.
Atossa Therapeutics | 10-Q: Quarterly report
Atossa Therapeutics Q1 2024 Adj EPS $(0.05) Beats $(0.07) Estimate
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent.
Atossa Therapeutics 1Q Loss/Shr 5c >ATOS
Atossa Therapeutics 1Q Loss/Shr 5c >ATOS
Press Release: Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update -- Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks -- I
Atossa Therapeutics Ended 1Q With $84M of Cash and Cash Equivalents and No Debt >ATOS
Atossa Therapeutics Ended 1Q With $84M of Cash and Cash Equivalents and No Debt >ATOS
Atossa Therapeutics Maintains Strong Cash Position While Advancing Breast Cancer Therapy in Q1 | NASDAQ:ATOS
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks Initiated study evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO)Ended first quarter 2024 with $84.
Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines
SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company") today announced its support of new guidelines released by the U.S. Preventive Services
Atos Receives Four Restructuring Proposals -- Update
By Michael Susin I.T. French firm Atos said it has received four new financial restructuring proposals as part of its refinancing process, aimed to trim its debt pile and restore profitability. Shar
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response
USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In ...
Atossa Therapeutics Announces Expanded Research Agreement With Weill Cornell Medicine
Analysis
Price Target
No Data
